38 results about "Protease-activated receptor" patented technology

The present disclosure is directed to human protease activated receptor 4 (PAR4) binding proteins (e.g. antibodies). In particular, anti-PAR4 binding proteins which are antagonists of human PAR4, as well as methods and uses thereof.

The invention relates to the use of a compound of Formula I for the treatment of protease-activated receptor mediated diseases by the administration of a compound of Formula I or a prodrug or metabolite thereof.

The invention relates to the field of thrombotic disease related drugs and particularly relates to novel PAR (Protease Activated Receptor)-1 antagonists with halogenated tetrazole acetophenone structures, preparation methods of the PAR-1 antagonists, pharmaceutical compositions containing the PAR-1 antagonists and applications of the PAR-1 antagonists to preparation of drugs for treating thrombotic diseases. The group R is defined as the specification.

The present invention provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for therapies such as metabolic syndrome, obesity, type II diabetes, fibrosis and cardiovascular diseases, whether they are used alone or in combination with other treatment modalities.

The invention relates to the field of thrombotic disease related drugs, belongs to triazole Schiff base compounds with brand new structures and derivatives of the triazole Schiff base compounds and particularly relates to PAR (Protease Activated Receptor)-1 antagonists with terminally-disubstituted triazole Schiff base structures, preparation methods of the PAR-1 antagonists, pharmaceutical compositions containing the PAR-1 antagonists and applications of the PAR-1 antagonists to preparation of drugs for treating thrombotic diseases. All the substituent groups are defined as the specification.

The invention relates to a whitening composition and its preparation method and application. In terms of the mass percentage of the whitening composition, the whitening composition includes the following components: emblica extract: 0.01%-10%, soybean extract: 0.01%-20%, aloin: 0.01%-5% %, ascorbic acid ethyl ether: 0.3% to 5%, nicotinamide: 0.5% to 20%. The whitening composition of the present invention can achieve a balanced whitening effect, that is, it can comprehensively consider all aspects of skin whitening. Specifically, it can start from the process of melanin production, reduce melanin, block the transfer process of melanin, induce and block the protease-activated receptor-2 channel, reduce the phagocytosis of melanosomes by keratinocytes, reduce the transport of melanin, and prevent melanin from entering the cutin Layers and other aspects play a role.

This invention is in the field of medicinal pharmacology. In particular, the invention relates to protease activated receptor type 2 (PAR2) modulating compounds (e.g., mimetic peptides), compositions comprising such modulating compounds, and their use as therapeutics for the treatment of conditions involving PAR2 activity.